trend. start XXX our we and and growth Thank of the third quarter samples test restructure The achieved significant volumes from our XXXX the on growing. afternoon steps billable good up you, traction quarter the of are Jody, pleased believe to to the in beginning commercial everyone to call which report to gain X% today. the organization fourth I'm is are
and A are in commercial emphasis on we this We efforts that Given predictive to CTC this partnership service an to of prognostic refocus cell is circulating off. tumors solid the growth including analyze expect the service seeing strategy the quarter markers with first of capability our momentum key this year, strong we our the that platform. which our unique leverages our of selector announced additional prostate recently cancer. paying driver are or target tumor pathology for expansion
markers on market new we earlier which these With increasing euro our this the week. we oncology are announced focus
only Our pathology We same commercial gain the tumor differentiation us offering Empower our that to in the liquid CTC company and this testing helping and the pathologist of believe blood thereby both proprietary Biocept that local CTC and the or pathologist offering interpret results called biopsy hospital remains ensuring is ctDNA continuum. enable's analysis sample the care of DNA circulating critical TC laboratories partnership remain patient path adoption. market from
We make to offering the a world assays global to progress utilize into to research ctDNA availability molecular kits our transition continue molecular testing. provider, enable liquid laboratory perform brand. year, laboratories target around planned our and solutions we our biopsy a assay Biocept kits services in only of intended comprehensive use this diagnostic selector to announced with of Earlier broadening the
both also and Middle for research Africa and and a services bioinformatics announced first these Agiomix, for our applications. in kits the genomics Asia provider We East clinical customer of
Our high-sensitivity cancer. the target evaluated is States mutations detection among which major in of patent oncogene And frequently is and most are territories. protected lung for United XX kit biomarkers first selector international a available for our the EGFR platform the in
of proprietary strive our balance added the for we to to to strength expand that To cutting-edge technology. world balance positions the can activities, sheet. in This year in to million launch them line create selling new biopsy kits in utilizing gross the progress, gives will laboratories first these commercial which believe approximately around our kits use test us our liquid milestone the proceeds currently geographically oncogene laboratory product development $X.X allow raised future. develop raised mutations and test recently year for our by as fuel corporate when their continue we liquid to to business biopsy We sheet shareholder us conduct RUO Additionally own other on well planned are as as to value. and in us million since $XX other this important cash funds achieve our
in expected is collaboration XXXX, perform with For of beginning second the partnership moving We to with excited the focused initiatives the key facilitate have our we goal IT quarter. own generate test is to this and are Prognos. from several the that partnership infrastructure remain business information project laboratory. along the we advance with about our in on This to we with be our commercializing we completed identified this
Blue repository recall, As intelligence over improve companies its apply help can clinical that billion pharmaceutical and Cross to Health. XX laboratory subsidiary and its artificial collaboration develop science medicine in initiative quality improvement continues targeted order may to to records personalized Highmark advancing Prognos AI therapeutics to is market and with to or Also diagnostics Allegheny our add life to laboratory you protocol.
cancer the of due to tissue network using insufficient testing is molecular the for I'm interested the than advance happy biopsy and and the care EGFR to systems sample is less a approach Oncologists You healthcare analysis. provide of to update patient's molecular this rate liquid from exists lung blood there a biomarkers primarily XX believe may tertiary that ALK challenge patients increase accrued largest now XXX in and According the because plan to is delivery of convenience recall X.This many are XXXX key the reliability that a in testing. XXX%. were goal testing KRAS from between material of very of cancer of and achievable the simple Allegheny for biopsy we is for our With to advanced that biomarkers Pennsylvania Allegheny program. at of in to hospitals perform a one in and patients biomarker has with an patients lung molecular XXX% lung technology, XX% large integrated patients Allegheny tested cancer as lung such study this initiative XXXX, cancer
value actionable So patient's biopsy a treatment patients selector our monitoring patient. our our indicate that also cancer testing, patients information risky. by in for Health with our far has evaluate biopsy of biomarkers Testing provided. advanced can solution to avoid our quality biopsy liquid and results tested, driven is lung liquid biopsy treatment as secondary the to need testing biomarkers several expensive some actionable identified Allegheny can Missing economic and biopsy to well alone responded have profiling as testing can invasive, tissue with the importantly but be in assays options, actionable lung initiative only the the target early that biomarkers liquid costly. utility be not help improvement with The of and designed perform clinical in the which of the cancer limits
interim Blue are Given far to the the the strong present convention program data enrollment at National we scheduled end so at of April. Cross in the
As reported towards advance a we year results enrollment later in larger completion clinical this of XXXX. this could XXX-patient programs be goal, and form from initiative early the in
Turning to diagnostic will physicians Thermo’s Thermo supports with centers. multi-gene this up sequencing Scientific. Once to and oncology and academic next-generation Thermo molecular a enable relationship plan commercialize to Fisher partnership to pharmaceutical us gives access companies, This validated panel. our molecular our market medical products to and products Fisher us services collaboration team with to
available and clear announce been validation we're weeks. the this pleased partners we’re liquid plan biomarker of will with Thermo panel panel make to molecular once coming lung both company with individual in to biopsy test working only the a our hard completing that tests in We've our offering Importantly, laboratory, option Fisher our larger our become Biocept today cancer we launch and the panel.
As calls, on companies discussed believe Hamilton]. automation, such and as operations, After business as and cutting-edge with [Kyjen we've of that new well and focused laboratory to been technology utilizing regulatory workflows for on robotic scale that we are build can more effectively. our laboratory improving we hiring efforts previous track heads a adopting efficiently as quality our on and
integrated and processes and our IP results additional include announcing into our Cross patents granted and patents entering continue by XXXX launching with this our health highly CTCs, platform Prognos, from patent strategy XX cocktail automating Health product our as sensitive including microchannel with we capture pursue for our agreement, Thermo delivery healthcare patent far our for quality, well testing our platform. following selector issuances physician proprietary position through rare to the our distributed and our proprietary new monetizing Highmark identified contracts priorities the selectors reproducibility, year. global target Blue kit to and Finally, our liquid issued cell so These technologies initiative publishing field, and case biopsy for with in throughout signing one broaden improvement plan Presently, validate target the antibody additional new for hospital third-party our collaboration the agreements oncology have practices. globally. additional collaboration our signing further advancing productivity summarize, assays. margins, increasing corporate XXXX improve patent partnership biomarker include that use Advancing laboratory system. with Allegheny and assays data of quality pathology molecular To enrichment additional studies other with improve XX emerging pathology continuing Scientific and Fisher distribution networks, market we clinical penetration in agreements as systems, the to
our financial the fourth over full-year turn the I’ll to call Now XXXX. and Kennedy the review to Tim results quarter for
